https://www.targetedonc.com/view/flot-vs-cross-in-resectable-gej-adenocarcinoma-which-regimen-is-best-
Late Stage Cancer
March 28, 2024
atients With Esophageal Cancer Have ‘More Options’ With Tevimbra
https://www.curetoday.com/view/patients-with-esophageal-cancer-have-more-options-with-tevimbra
March 17, 2024
FDA Approves Tevimbra, BeiGene’s Treatment for Adults with Unresectable or Metastatic Esophageal Squamous Carcinoma
https://www.pharmexec.com/view/fda-approves-tevimbra-beigene-s-treatment-for-adults-with-unresectable-or-metastatic-esophageal-squamous-carcinoma
February 29, 2024
Dr Shah on Responses With Pembrolizumab Plus Chemo By PD-1 Status in Esophageal Cancer
https://www.onclive.com/view/dr-shah-on-responses-with-pembrolizumab-plus-chemo-by-pd-1-status-in-esophageal-cancer
February 26, 2024
Immunotherapy for Resectable Locally Advanced Esophageal Carcinoma
https://www.sciencedirect.com/science/article/abs/pii/S0003497524001255
January 17, 2024
KEYNOTE-590: Long-term Outcomes of First-line Pembrolizumab, Chemotherapy for Advanced Esophageal Cancer
https://www.docwirenews.com/post/keynote-590-long-term-outcomes-of-first-line-pembrolizumab-chemotherapy-for-advanced-esophageal-cancer
January 12, 2024
Nivolumab Plus Chemotherapy Demonstrates Superior OS in Esophageal/Gastric Cancer
https://www.targetedonc.com/view/nivolumab-plus-chemotherapy-demonstrates-superior-os-in-esophageal-gastric-cancer
December 20, 2023
Shitara and Xu Discuss Potential FDA Approval of Zolbetuximab in CLDN18.2+ Gastric/GEJ Adenocarcinoma
https://www.onclive.com/view/shitara-and-xu-discuss-potential-fda-approval-of-zolbetuximab-in-cldn18-2-gastric-gej-adenocarcinoma?utm_source=www.onclive.com&utm_medium=relatedContent
December 9, 2023
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
https://finance.yahoo.com/news/cstone-announces-nmpa-approval-sugemalimab-041000120.html